The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | The future of CAR-T therapy: earlier use, new indications, & improved manufacturing
Christian Buchholz, PhD, Paul-Ehrlich-Institut, Langen, Germany, discusses advances in chimeric antigen receptor T-cell (CAR-T) therapy. Originally approved in B-cell precursor acute lymphoblastic leukemia (B-ALL), new CAR-T approaches are now being developed for a wider range of indications including other lymphoma subtypes and multiple myeloma. In addition, whilst CAR-Ts have only been approved in the third-line setting in lymphoma, there is an increasing body of evidence suggesting that these cellular therapies might be beneficial in earlier lines of treatment. In parallel, Dr Buchholz explains that companies are working on decreasing CAR-T manufacturing costs, thus making this treatment available for a larger number of patients. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
